Sanofi and Provention Bio entered into an agreement under which Sanofi has agreed to acquire Provention Bio, for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
The acquisition of Provention Bio builds on Sanofi
Found this useful? Share it with your team.
